Table 3.
Treatment modalities according to age
| Treatment modalities | Age at consent for patients with history of renal angiomyolipoma, n = 1070 |
||||||
|---|---|---|---|---|---|---|---|
| ≤2 (n = 25) | >2 to ≤5 (n = 77) | >5 to ≤9 (n = 134) | >9 to ≤14 (n = 159) | >14 to ≤18 (n = 103) | >18 to ≤40 (n = 393) | >40 (n = 179) | |
| Patients received treatment, n (%) | 1 (4.0) | 1 (1.3) | 11 (8.2) | 24 (15.1) | 27 (26.0) | 158 (40.2) | 87 (48.6) |
| Type of treatmenta, n (%) | |||||||
| Dialysis | 0 | 0 | 0 | 0 | 0 | 2 (1.3) | 1 (1.1) |
| Embolization | 0 | 0 | 0 | 2 (8.3) | 7 (25.9) | 83 (52.5) | 50 (57.5) |
| Nephrectomy | 0 | 0 | 0 | 2 (8.3) | 3 (11.1) | 29 (18.4) | 28 (32.2) |
| Resection | 0 | 0 | 1 (9.1) | 1 (4.2) | 3 (11.1) | 10 (6.3) | 5 (5.7) |
| mTOR inhibitor | 1 (100.0) | 1 (100.0) | 11 (100.0) | 17 (70.8) | 16 (59.3) | 67 (42.4) | 21 (24.1) |
| Others | 0 | 0 | 0 | 0 | 0 | 9 (5.7) | 4 (4.6) |
a
Used alone or in combination with other treatment modalities.